{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:53:01Z","timestamp":1775512381654,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Central Health Care Physician Training grant"},{"name":"Personalized Therapy for Lung Cancer Gift Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13045-017-0433-z","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T10:22:27Z","timestamp":1488277347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Hong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken Y.","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee L. Q.","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Molmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"433_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med"},{"key":"433_CR2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350.","journal-title":"Lancet"},{"key":"433_CR3","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837\u201346.","journal-title":"Lancet"},{"key":"433_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","author":"A Rittmeyer","year":"2016","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016. doi: 10.1016\/S0140-6736(16)32517-X .","journal-title":"Lancet"},{"key":"433_CR5","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"433_CR6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299\u2013308.","journal-title":"Lancet Oncol"},{"key":"433_CR7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med. 2015;373:288\u201390.","journal-title":"N Engl J Med"},{"key":"433_CR8","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051\u201360.","journal-title":"Clin Cancer Res"},{"key":"433_CR9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"433_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2016. doi: 10.1200\/JCO.2016.68.2005 .","journal-title":"J Clin Oncol"},{"key":"433_CR11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607\u201316.","journal-title":"JAMA Oncol"},{"key":"433_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-016-0309-7","volume":"9","author":"M Uemura","year":"2016","unstructured":"Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, et al. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn\u2019s disease: a case report. J Hematol Oncol. 2016;9:81.","journal-title":"J Hematol Oncol"},{"key":"433_CR13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331.","journal-title":"Nat Biotechnol"},{"key":"433_CR14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"issue":"16_suppl","key":"433_CR15","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","volume":"34","author":"DR Spigel","year":"2016","unstructured":"Spigel DR, Schrock AB, Fabrizio D, Frampton GM, Sun J, He J, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies. J Clin Oncol. 2016;34(16_suppl):9017.","journal-title":"J Clin Oncol"},{"key":"433_CR16","doi-asserted-by":"crossref","first-page":"77P","DOI":"10.1093\/annonc\/mdw363.25","volume":"27","author":"M Kowanetz","year":"2016","unstructured":"Kowanetz M, Zou W, Shames DS, Cummings C, Rizvi N, Spira AI, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Ann Oncol. 2016;27:77P.","journal-title":"Ann Oncol"},{"key":"433_CR17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","volume":"481","author":"M Greaves","year":"2012","unstructured":"Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306\u201313.","journal-title":"Nature"},{"key":"433_CR18","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546\u201358.","journal-title":"Science"},{"key":"433_CR19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"433_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","volume":"9","author":"W Ma","year":"2016","unstructured":"Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9:47.","journal-title":"J Hematol Oncol"},{"key":"433_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-016-0259-0","volume":"9","author":"KH Chen","year":"2016","unstructured":"Chen KH, Yuan CT, Tseng LH, Shun CT, Yeh KH. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. J Hematol Oncol. 2016;9:29.","journal-title":"J Hematol Oncol"},{"key":"433_CR22","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1158\/2159-8290.CD-16-0177","volume":"6","author":"SC Akincilar","year":"2016","unstructured":"Akincilar SC, Khattar E, Boon PL, Unal B, Fullwood MJ, Tergaonkar V. Long-range chromatin interactions drive mutant TERT promoter activation. Cancer Discov. 2016;6:1276\u201391.","journal-title":"Cancer Discov"},{"key":"433_CR23","doi-asserted-by":"crossref","first-page":"e0146803","DOI":"10.1371\/journal.pone.0146803","volume":"11","author":"P Yuan","year":"2016","unstructured":"Yuan P, Cao JL, Abuduwufuer A, Wang LM, Yuan XS, Lv W, et al. Clinical characteristics and prognostic significance of TERT promoter mutations in cancer: a cohort study and a meta-analysis. PLoS One. 2016;11:e0146803.","journal-title":"PLoS One"},{"key":"433_CR24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"433_CR25","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2016-CT001","volume":"76","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Kluger H, Sznol M, Carvajal R, Lawrence D, Atkins M, et al. Abstract CT001: durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Cancer Res. 2016;76:CT001.","journal-title":"Cancer Res"},{"key":"433_CR26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","volume":"21","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21:634\u201342.","journal-title":"Oncologist"},{"key":"433_CR27","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384\u201391.","journal-title":"J Clin Invest"},{"key":"433_CR28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PPO.0000000000000061","volume":"20","author":"MF Sanmamed","year":"2014","unstructured":"Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20:256\u201361.","journal-title":"Cancer J"},{"key":"433_CR29","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2:1403\u20134.","journal-title":"JAMA Oncol"},{"key":"433_CR30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-017-0403-5","volume":"10","author":"J Wang","year":"2017","unstructured":"Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10:34.","journal-title":"J Hematol Oncol"},{"key":"433_CR31","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.18632\/oncotarget.6960","volume":"7","author":"S Kalaora","year":"2016","unstructured":"Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget. 2016;7:5110\u20137.","journal-title":"Oncotarget"},{"key":"433_CR32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747\u201352.","journal-title":"Nat Med"},{"key":"433_CR33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/jir.2012.0136","volume":"34","author":"GS Pandey","year":"2014","unstructured":"Pandey GS, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. J Interferon Cytokine Res. 2014;34:931\u20137.","journal-title":"J Interferon Cytokine Res"},{"key":"433_CR34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","volume":"388","author":"FR Hirsch","year":"2016","unstructured":"Hirsch FR, Suda K, Wiens J, Bunn Jr PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388:1012\u201324.","journal-title":"Lancet"},{"key":"433_CR35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-016-0365-z","volume":"9","author":"B Dholaria","year":"2016","unstructured":"Dholaria B, Hammond W, Shreders A, Lou Y. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016;9:138.","journal-title":"J Hematol Oncol"},{"key":"433_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-016-0054-1","volume":"5","author":"EC Hsueh","year":"2015","unstructured":"Hsueh EC, Gorantla KC. Novel melanoma therapy. Exp Hematol Oncol. 2015;5:23.","journal-title":"Exp Hematol Oncol"},{"key":"433_CR37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-016-0278-x","volume":"9","author":"GJ McCaughan","year":"2016","unstructured":"McCaughan GJ, Fulham MJ, Mahar A, Soper J, Hong AM, Stalley PD, et al. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol. 2016;9:48.","journal-title":"J Hematol Oncol"},{"key":"433_CR38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-016-0328-4","volume":"9","author":"GS Alexander","year":"2016","unstructured":"Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, et al. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol. 2016;9:96.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-017-0433-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T01:24:42Z","timestamp":1568856282000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-017-0433-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1186\/s13045-017-0433-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]},"article-number":"64"}}